Market Overview
The market reflects a high disease burden driven by South Korea's rapidly aging demographics and westernized dietary patterns, with diabetes prevalence steadily climbing across adult age groups. Domestic manufacturers have gained meaningful market share through competitive pricing and localized innovation, while global leaders maintain strong positions in premium device and biologic segments.
- •Combined drugs and devices market valued at $36.97 billion in 2025, growing at a 10.96% CAGR
- •Broad NHIS reimbursement coverage underpins demand for both therapeutics and monitoring devices
- •High diabetes prevalence among South Korea's aging population fuels sustained market expansion
Growth Drivers
Technological innovation is accelerating adoption of connected devices, with continuous glucose monitors and automated insulin delivery systems gaining significant traction as healthcare providers and patients seek tighter glycemic control. Expanding insurance reimbursement for digital diabetes tools and biosimilar biologics further supports market expansion across price segments.
- •Government initiatives through Korea's National Diabetes Management Program expand screening and subsidized treatment access
- •Growing adoption of CGM systems and hybrid closed-loop insulin delivery technology
- •Rising demand for biosimilar insulin and cost-effective diabetes drug alternatives
Segmentation and Regional Analysis
Distribution channels remain dominated by hospital pharmacies and retail outlets, with online pharmacies and diabetes specialty clinics expanding rapidly as digital health adoption accelerates. Seoul metropolitan area and Gyeonggi Province account for the largest share of demand, though regional cities including Busan and Daegu are experiencing accelerating growth as healthcare infrastructure improves outside the capital.
- •Seoul and Gyeonggi Province represent the largest regional demand centers
- •Hospital pharmacies lead distribution, while online pharmacy channels are growing fastest
- •CGM and insulin pump segments expanding at above-market rates
Trends and Outlook
What are the recent trends and outlook?
The market outlook through 2030 remains strongly positive, underpinned by continued demographic pressures, expanding insurance coverage for advanced technologies, and intensifying competition from biosimilar and GLP-1 drug entrants. Personalized combination therapies, patch-based insulin delivery systems, and deeper AI integration are expected to define innovation trajectories for both domestic and international market participants.
- •Telehealth and AI-powered diabetes management platforms gaining regulatory and market acceptance
- •Biosimilar competition intensifying across insulin and GLP-1 drug categories
- •Shift toward personalized combination therapies and digital-first chronic disease management models
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.